U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman

Merck's got a green light from the 's effectiveness to treat patients with , chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.

 

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS